Viking Therapeutics Set for Multiple Investor Conference Appearances
Viking Therapeutics Set for Multiple Investor Conference Appearances
Viking Therapeutics, Inc. (NASDAQ: VKTX) is excited to share that it will participate in several upcoming investor conferences aimed at highlighting its advancements in biopharmaceutical development. As a clinical-stage company, Viking focuses on innovative therapies for metabolic and endocrine disorders. Upcoming events present a unique opportunity for the company to engage with potential investors and discuss its promising drug developments, innovations, and the transformative potential of its therapies.
Details of Upcoming Conferences
Here are the key details regarding Viking's participation in the upcoming conferences:
William Blair 45th Annual Growth Stock Conference
At this conference, Viking's management will deliver a comprehensive corporate presentation and engage in a fireside chat along with one-on-one meetings.
- Conference Dates: June 3-5
- Presentation Timing: 2:00 – 2:30 p.m. Central on Tuesday, June 3
- Location: Chicago
Jefferies Global Healthcare Conference
This conference will feature another presentation by Viking management, followed by one-on-one meetings with interested investors.
- Conference Dates: June 3-5
- Presentation Timing: 11:40 a.m. – 12:10 p.m. Central on Thursday, June 5
- Location: New York, in addition to a webcast available for online attendees
46th Annual Goldman Sachs Global Healthcare Conference
During this prestigious conference, Viking management will participate in one-on-one discussions with investors to detail the company's progress and strategic direction.
- Conference Dates: June 9-11
- Location: Miami
Scotiabank Third Annual Healthcare Canadian Investor Day
Viking will again engage with investors through one-on-one meetings during this event, solidifying its commitment to transparency and investor relations.
- Conference Date: June 17
- Location: Toronto, Canada
Webcasts and Conference Access
Viking Therapeutics will also provide live access to the Jefferies conference presentations, allowing broader participation from interested stakeholders. Details regarding accessing the live webcast can be found on Viking's official website in the Investors & Media section. A replay of the presentation will be accessible afterward for those unable to attend live.
About Viking Therapeutics, Inc.
Viking is committed to revolutionizing the treatment landscape for metabolic and endocrine disorders through its robust pipeline. The company is actively developing several therapies, including VK2735, an innovative dual agonist targeting GLP-1 and GIP receptors. This therapy shows great promise in clinical trials for various metabolic disorders, demonstrating a favorable safety profile and potential clinical benefits.
Further, Viking continues to advance VK2809, designed to treat lipid and metabolic disorders, which has successfully met key endpoints in recent studies. As part of its research efforts, the company is also examining a series of dual amylin and calcitonin receptor agonists for the treatment of obesity. Finally, VK0214 is being developed for X-linked adrenoleukodystrophy (X-ALD), proving to be safe and effective in early clinical trials.
For more insights about Viking Therapeutics, please visit www.vikingtherapeutics.com.
Frequently Asked Questions
What is Viking Therapeutics known for?
Viking Therapeutics specializes in the development of innovative therapies for metabolic and endocrine disorders.
What conferences will Viking participate in?
Viking is participating in the William Blair, Jefferies, Goldman Sachs, and Scotiabank conferences, among others.
When will Viking present at the Jefferies conference?
Viking's presentation at the Jefferies Global Healthcare Conference is scheduled for June 5.
What are VK2735 and VK2809?
VK2735 is a dual agonist for metabolic disorders, while VK2809 is targeted for lipid and metabolic disorders. Both are in various stages of clinical trials.
How can I access the conference presentations?
Live webcasts of the conferences will be available on Viking's website, along with replays after the events conclude.
About The Author
Contact Hannah Lewis privately here. Or send an email with ATTN: Hannah Lewis as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.